NO20081211L - Xantinderivater som selektive HM74A agonister - Google Patents

Xantinderivater som selektive HM74A agonister

Info

Publication number
NO20081211L
NO20081211L NO20081211A NO20081211A NO20081211L NO 20081211 L NO20081211 L NO 20081211L NO 20081211 A NO20081211 A NO 20081211A NO 20081211 A NO20081211 A NO 20081211A NO 20081211 L NO20081211 L NO 20081211L
Authority
NO
Norway
Prior art keywords
xanthine derivatives
hm74a agonists
compounds
selective
derivatives
Prior art date
Application number
NO20081211A
Other languages
English (en)
Norwegian (no)
Inventor
Andrew Mcmurtrie Mason
Ivan Leo Pinto
Richard Jonathan Daniel Hatley
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0516464A external-priority patent/GB0516464D0/en
Priority claimed from GB0607736A external-priority patent/GB0607736D0/en
Priority claimed from GB0614569A external-priority patent/GB0614569D0/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20081211L publication Critical patent/NO20081211L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20081211A 2005-08-10 2008-03-07 Xantinderivater som selektive HM74A agonister NO20081211L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0516464A GB0516464D0 (en) 2005-08-10 2005-08-10 Novel compounds
GB0607736A GB0607736D0 (en) 2006-04-19 2006-04-19 Novel compounds
GB0614569A GB0614569D0 (en) 2006-07-21 2006-07-21 Novel compounds
PCT/EP2006/007865 WO2007017261A1 (en) 2005-08-10 2006-08-08 Xanthine derivatives as selective hm74a agonists

Publications (1)

Publication Number Publication Date
NO20081211L true NO20081211L (no) 2008-05-08

Family

ID=37189397

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20081211A NO20081211L (no) 2005-08-10 2008-03-07 Xantinderivater som selektive HM74A agonister
NO20081212A NO20081212L (no) 2005-08-10 2008-03-07 Xantinderivater som selektive HM74A agonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20081212A NO20081212L (no) 2005-08-10 2008-03-07 Xantinderivater som selektive HM74A agonister

Country Status (28)

Country Link
US (3) US20100179128A1 (enExample)
EP (3) EP1912992A1 (enExample)
JP (2) JP5112316B2 (enExample)
KR (2) KR20080034993A (enExample)
AR (1) AR055369A1 (enExample)
AT (1) ATE487719T1 (enExample)
AU (2) AU2006278216A1 (enExample)
BR (2) BRPI0614270A2 (enExample)
CA (2) CA2618963A1 (enExample)
CR (2) CR9749A (enExample)
CY (1) CY1111757T1 (enExample)
DE (1) DE602006018151D1 (enExample)
DK (1) DK1912991T3 (enExample)
EA (2) EA200800564A1 (enExample)
ES (1) ES2401128T3 (enExample)
HR (1) HRP20100725T1 (enExample)
IL (2) IL189083A0 (enExample)
MA (2) MA29693B1 (enExample)
MX (2) MX2008001931A (enExample)
MY (1) MY142067A (enExample)
NO (2) NO20081211L (enExample)
NZ (1) NZ565494A (enExample)
PE (1) PE20070405A1 (enExample)
PL (1) PL1912991T3 (enExample)
PT (1) PT1912991E (enExample)
SI (1) SI1912991T1 (enExample)
TW (1) TW200800217A (enExample)
WO (2) WO2007017261A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
HRP20130406T1 (hr) * 2004-02-14 2013-06-30 Glaxosmithkline Intellectual Property Development Limited Medikamenti s aktivnošä†u prema receptoru hm74a
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
JP5112316B2 (ja) * 2005-08-10 2013-01-09 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
ATE486874T1 (de) 2006-06-23 2010-11-15 Incyte Corp Purinonderivate als hm74a-agonisten
AR061625A1 (es) 2006-06-23 2008-09-10 Incyte Corp Derivados de purinona como agonistas de hm74a
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de) 2007-11-13 2009-07-23 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
RS53777B1 (sr) 2008-12-08 2015-06-30 Glaxosmithkline Llc Anhidrid 8-hlor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiola za lečenje bolesti
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101799429B1 (ko) * 2010-05-03 2017-11-21 에스케이바이오팜 주식회사 신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
AU2011292285A1 (en) * 2010-08-16 2013-01-31 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
US8580825B2 (en) * 2010-09-23 2013-11-12 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN104364249B (zh) * 2012-05-30 2018-04-17 霍夫曼-拉罗奇有限公司 作为pde10抑制剂的三唑并化合物
UA117470C2 (uk) * 2013-03-15 2018-08-10 Гайдра Байосаєнсиз, Інк. Заміщені ксантини та способи їх застосування
CA2911818A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
CN105358155A (zh) 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
MX2015015417A (es) * 2013-05-10 2016-06-21 Nimbus Apollo Inc Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
CA2911932A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
CN105646492B (zh) * 2014-11-14 2019-04-09 中国医学科学院药物研究所 含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途
DE102017000359A1 (de) 2016-08-26 2018-03-01 Bihl+Wiedemann Gmbh Diagnose-Repeater für AS-Interface Netze
JP7178357B2 (ja) * 2017-03-07 2022-11-25 エフ．ホフマン－ラ ロシュ アーゲー オキサジアゾール一過性受容器電位チャネル阻害剤
AU2019318209B2 (en) 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
CN112724141A (zh) * 2021-01-21 2021-04-30 南京艾美斐生物医药科技有限公司 一种gpr109a蛋白受体抑制剂及其制备和应用
CA3243510A1 (en) * 2022-02-03 2023-08-10 D.E. Shaw Research, Llc N3-SUPPOSED URACIL COMPOUNDS AS TRPA1 INHIBITORS
JP2026503850A (ja) * 2023-01-30 2026-01-30 ディー．イー．ショウ リサーチ，エルエルシー Ｔｒｐａ１阻害剤としての二環式イミド化合物
AR133217A1 (es) * 2023-07-10 2025-09-10 De Shaw Res Llc Inhibidores de trpa1 bicíclicos y monocíclicos

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797220A (en) 1954-12-02 1957-06-25 Univ Michigan Substituted paraxanthines
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
NZ240644A (en) 1990-11-21 1994-08-26 Smithkline Beecham Corp Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
AU3725893A (en) 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
ATE230990T1 (de) 1992-03-04 2003-02-15 Cell Therapeutics Inc Enantiomere hydroxylierte xanthinverbindungen
US5804584A (en) 1992-11-16 1998-09-08 Cell Therapeutics, Inc. Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms
US5473070A (en) 1992-11-16 1995-12-05 Cell Therapeutics, Inc. Substituted long chain alcohol xanthine compounds
US6469017B1 (en) 1998-01-16 2002-10-22 Cell Therapeutics, Inc. Method of inhibiting interleukin-12 signaling
US6693105B1 (en) 1992-11-16 2004-02-17 Cell Therapeutics, Inc. Hydroxyl-containing compounds
IL109161A0 (en) 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
AU6702894A (en) 1993-04-09 1994-11-08 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
US6780865B1 (en) 1994-02-18 2004-08-24 Cell Therapeutics, Inc. Compounds having selective hydrolytic potentials
US6878715B1 (en) 1994-02-18 2005-04-12 Cell Therapeutics, Inc. Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
AU1967495A (en) 1994-02-18 1995-09-04 Cell Therapeutics, Inc. Intracellular signalling mediators
US6103730A (en) 1994-03-24 2000-08-15 Cell Therapeutics, Inc. Amine substituted compounds
US5807861A (en) 1994-03-24 1998-09-15 Cell Therapeutics, Inc. Amine substituted xanthinyl compounds
US6323201B1 (en) * 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
WO2000061583A1 (en) 1995-06-07 2000-10-19 Cell Therapeutics, Inc. Xanthine derivatives and analogs as cell signaling inhibitors
AR015966A1 (es) 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
US20030207901A1 (en) 1999-07-27 2003-11-06 Cell Therapeutics, Inc. Hydroxyl-containing compounds
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
EE05643B1 (et) 2001-02-24 2013-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ksantiini derivaadid, nende valmistamine ja kasutamine ravimina
US20040254224A1 (en) 2001-04-11 2004-12-16 Foord Steven Michael Medicaments
EP1404675B1 (en) 2001-07-03 2008-03-12 Novo Nordisk A/S Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
EP1338595B1 (en) 2002-02-25 2006-05-03 Eisai Co., Ltd. Xanthine derivatives as DPP-IV inhibitors
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
CN1227492C (zh) * 2003-03-11 2005-11-16 张跃 一种吸收式空调主体
GB0319124D0 (en) * 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
HRP20130406T1 (hr) 2004-02-14 2013-06-30 Glaxosmithkline Intellectual Property Development Limited Medikamenti s aktivnošä†u prema receptoru hm74a
WO2006045564A1 (en) * 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
US20090209561A1 (en) * 2004-10-22 2009-08-20 Richard Jonathan Daniel Hatley Xanthine Derivatives with HM74A Receptor Activity
JP2008517029A (ja) * 2004-10-22 2008-05-22 スミスクライン・ビーチャム・コーポレイション Ｈｍ７４ａ受容体活性を有するキサンチン誘導体
US20080221108A1 (en) 2005-02-14 2008-09-11 Richard Hatley Anthranilic Acid Derivatives As Hm74A Receptor Agonists
GB0516462D0 (en) * 2005-08-10 2005-09-14 Smithkline Beecham Corp Novel compounds
JP5112316B2 (ja) * 2005-08-10 2013-01-09 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 選択的ｈｍ７４ａアゴニストとしてのキサンチン誘導体
DE102008009758A1 (de) * 2008-02-18 2009-08-20 Beiersdorf Ag Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite
RS53777B1 (sr) 2008-12-08 2015-06-30 Glaxosmithkline Llc Anhidrid 8-hlor-3-pentil-3,7-dihidro-1h-purin-2,6-dion 2-amino-2-(hidroksimetil)-1,3-propandiola za lečenje bolesti

Also Published As

Publication number Publication date
JP2009504592A (ja) 2009-02-05
TW200800217A (en) 2008-01-01
US20100168122A1 (en) 2010-07-01
MX2008001931A (es) 2008-03-24
KR20080034993A (ko) 2008-04-22
PE20070405A1 (es) 2007-05-06
PL1912991T3 (pl) 2011-04-29
CR9748A (es) 2008-05-05
NZ565494A (en) 2011-06-30
US20100179128A1 (en) 2010-07-15
EP2272848A1 (en) 2011-01-12
EP2272848B1 (en) 2012-12-26
WO2007017262A1 (en) 2007-02-15
CY1111757T1 (el) 2015-10-07
AU2006278216A1 (en) 2007-02-15
CA2618963A1 (en) 2007-02-15
NO20081212L (no) 2008-05-06
HRP20100725T1 (hr) 2011-01-31
DK1912991T3 (da) 2011-02-21
ES2401128T3 (es) 2013-04-17
MX2008001929A (es) 2008-03-24
DE602006018151D1 (de) 2010-12-23
MY142067A (en) 2010-08-30
SI1912991T1 (sl) 2011-03-31
PT1912991E (pt) 2011-01-17
HK1116779A1 (en) 2009-01-02
CA2626723A1 (en) 2007-02-15
EP1912991A1 (en) 2008-04-23
US8143264B2 (en) 2012-03-27
ATE487719T1 (de) 2010-11-15
AR055369A1 (es) 2007-08-22
US20110257205A1 (en) 2011-10-20
AU2006278215A1 (en) 2007-02-15
EA200800564A1 (ru) 2008-08-29
JP2009504591A (ja) 2009-02-05
EP1912992A1 (en) 2008-04-23
JP5112316B2 (ja) 2013-01-09
BRPI0615145A2 (pt) 2009-11-03
BRPI0614270A2 (pt) 2011-03-22
MA29693B1 (fr) 2008-08-01
IL189083A0 (en) 2008-08-07
WO2007017261A1 (en) 2007-02-15
EA200800555A1 (ru) 2008-08-29
EP1912991B1 (en) 2010-11-10
EA014556B1 (ru) 2010-12-30
MA29692B1 (fr) 2008-08-01
KR20080038396A (ko) 2008-05-06
IL189081A0 (en) 2008-08-07
CR9749A (es) 2008-05-22

Similar Documents

Publication Publication Date Title
NO20081212L (no) Xantinderivater som selektive HM74A agonister
NO20072548L (no) Xantinderivater med HM74A reseptoraktivitet
WO2007011833A3 (en) Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
TW200606162A (en) Pyrazolopyridine derivatives
NO20085176L (no) Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter
NO20073719L (no) Kjemiske forbindelser
SE0301010D0 (sv) Novel compounds
NO20074050L (no) Purinderivater som fungerer som A2A-receptoragonister
CY1112889T1 (el) Αναλογα αζετιδινης αναστολεων νουκλεοσιδασης και φωσφορυλασης
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
SE0301009D0 (sv) Novel compounds
MX2009006267A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa.
NO20084747L (no) Tetrahydropteridiner anvendbare som inhibitorer av protein kinaser
NO20064151L (no) Nye forbindelser
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
WO2007068894A3 (en) Substituted diphenylethers, -amines, -sulfides and -methanes for the treatment of respiratory disease
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
NO20072290L (no) Organiske forbindelser.
NO20061952L (no) Pyrimidin-2-aminderivater og deres anvendelse som A2B-adenosinreseptorantagonister
NO20073631L (no) Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel
WO2006096444A3 (en) Chemical compounds

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application